Orphazyme A/S

Orphazyme A/S

Orphazyme A/S

Overview
Date Founded

2009

Headquarters

Ole Maaløes Vej 3,Copenhagen, Capital Region 2200

Type of Company

Public

Employees (Worldwide)

141

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Contact Data
Trying to get in touch with decision makers at Orphazyme A/S? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & CSO

Chief Executive Officer

Chief Financial Officer

Chief Commercial Officer

Chief Medical Officer

Chief Business Officer

US President

Global & US Head of Corporate Communications

Senior Manager-Research & Development

Senior Science Manager

Board of Directors

Former Executive Vice President-Therapeutics at Genzyme Corp.

Chairman & Chief Executive Officer at MedDay Pharmaceuticals SAS

Chief Executive Officer at Inthera Bioscience AG

Founder at LSP Management Group BV

Managing Partner at Kurma Partners SA

Chief Medical Officer at E-Scape Bio, Inc.

Chief Executive Officer at Rodenstock GmbH

General Partner & Founder at Sunstone Capital A/S

Former GM-Rare Disease Business Unit & Senior Vice President at Genzyme Corp.

Paths to Orphazyme A/S
Potential Connections via
Relationship Science
You
Orphazyme A/S
Owners & Shareholders
Details Hidden

Consonance Capital aims to deliver exceptional, uncorrelated risk-adjusted returns through investment opportunities in the publicly traded stocks of healthcare companies. The firm seeks to meet this strategy by investing in publicly traded micro-cap, small-cap and mid-cap healthcare equities. They believe the public healthcare market lends itself to an active long/short strategy. Consonance Capital is focused on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The firm seeks to identify and analyze companies trading below their intrinsic value, which may include deep value as well as growth companies.

Details Hidden

Perinvest UK aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon. Perinvest UK's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Details Hidden

Perinvest UK aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon. Perinvest UK's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Recent Transactions
Details Hidden

Orphazyme A/S issued USD American Depositary Shares

Details Hidden

Orphazyme A/S issued DKK Ordinary Shares

Transaction Advisors
Global Coordinator

Advised onOrphazyme A/S issued USD American Depositary Shares

Global Coordinator

Advised onOrphazyme A/S issued DKK Ordinary Shares

Escrow Agent

Advised onOrphazyme A/S issued USD American Depositary Shares

Clients

Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires rights to niche hospital-only and critical care products and also provides access to licensed and branded generic. The Unlicensed Medicines segment supplies unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Services offers comparator medicines and services to clinical trials and IITs. The company was founded by Andrew Leaver in June 2010 and is headquartered in Burton-on-Trent, the United Kingdom.

Key Stats and Financials As of 2020
Market Capitalization
$557M
Total Enterprise Value
$187M
Earnings Per Share
$-3.35
TEVNet Income
-1.97x
Debt TEV
0.06x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Total Debt
$10.6M
Total Equity
$93.2M
EBITDA
$-90.6M
Revenue
$0
Net Profit
$-95.1M
Investors
Details Hidden

KP is an active manager which invest in startups located in Europe. The firm targets companies operating in the fields of healthcare services and health technologies. KP provides financing from seed stage to growth stage capital requirements.

Details Hidden

Chief Executive Officer & Director at Dansk Biotek

Details Hidden

Former Director at Orphazyme A/S

Suppliers
University College London London, United Kingdom

University College London (UCL) is a public research university in London, England, and the oldest and largest constituent college of the federal University of London. Founded in 1826 as London University, UCL was the first university institution established in London and the first in England to be entirely secular, to admit students regardless of their religion, and to admit women on equal terms with men. The philosopher Jeremy Bentham is commonly regarded as the spiritual father of UCL, as his radical ideas on education and society were the inspiration to its founders, although his direct involvement in its foundation was limited. UCL became one of the two founding colleges of the University of London in 1836. It has grown through mergers, including with the Institute of Neurology (in 1997), the Royal Free Hospital Medical School (in 1998), the Eastman Dental Institute (in 1999), the School of Slavonic and East European Studies (in 1999) and the School of Pharmacy (in 2012). UCL's main campus is located in the Bloomsbury area of central London, with a number of institutes and teaching hospitals located elsewhere in central London, and satellite campuses in Adelaide, Australia and Doha, Qatar. UCL is organised into 10 constituent faculties, within which there are over 100 departments, institutes and research centres. UCL has around 26,700 students and 11,025 staff and had a total income of £937 million in 2012/13, of which £335 million was from research grants and contracts. UCL has around 4,000 academic and research staff and 650 full professors, the highest number of any British university. UCL is responsible for several museums and collections in a wide range of fields across the arts and sciences, including the Petrie Museum of Egyptian Archaeology, a leading collection of Egyptian and Sudanese archaeology.

University of Kansas Private Equity & Venture Capital | Lawrence, usa

The University of Kansas (KU) is a public research university and the largest university in the State of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The University was opened in 1866, under a charter granted by the Kansas Legislature in 1864.

CytRx Corp. Medical Support Services | Los Angeles, CA

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Biogen, Inc. Biotechnology - Cambridge, MA

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Orphazyme A/S. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Orphazyme A/S's profile does not indicate a business or promotional relationship of any kind between RelSci and Orphazyme A/S.